- Home
- LEGN vs KNSA Comparison
LEGN vs KNSA Comparison
Compare LEGN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGN | KNSA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.9B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LEGN | KNSA |
|---|---|---|
| Price | $17.73 | $74.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $61.33 | $60.86 |
| AVG Volume (30 Days) | ★ 1.6M | 421.3K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $42.68 | $37.48 |
| Revenue Next Year | $30.52 | $17.87 |
| P/E Ratio | ★ N/A | $282.48 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $16.24 | $35.29 |
| 52 Week High | $37.50 | $82.94 |
Technical Indicators
Market Signals| Indicator | LEGN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 49.48 |
| Support Level | $17.81 | $44.95 |
| Resistance Level | $19.36 | $81.97 |
| Average True Range (ATR) | 0.85 | 2.45 |
| MACD | -0.17 | -0.82 |
| Stochastic Oscillator | 8.33 | 24.66 |
Price Performance
Historical ComparisonAbout LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.